PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33663041-9 2021 CONCLUSION: Avanafil 200 mg on demand has the highest probability of being the best intervention among PDE5is in treating ED following NSRP. avanafil 12-20 phosphodiesterase 5A Homo sapiens 103-107 35119252-6 2022 Different drugs inhibiting PDE5 (PDE5i) exist, the main of which commercially available are sildenafil, vardenafil, tadalafil, and avanafil. avanafil 131-139 phosphodiesterase 5A Homo sapiens 27-31 35119252-6 2022 Different drugs inhibiting PDE5 (PDE5i) exist, the main of which commercially available are sildenafil, vardenafil, tadalafil, and avanafil. avanafil 131-139 phosphodiesterase 5A Homo sapiens 33-38 35396013-2 2022 It is part of a new generation of PDE5 inhibitors that includes udenafil and avanafil. avanafil 77-85 phosphodiesterase 5A Homo sapiens 34-38 27377089-6 2016 CONCLUSIONS: Among PDE5 inhibitors, Avanafil is a new agent with an intermediate duration of action, characterized by high efficacy and good tolerability even at the highest dose (200 mg). avanafil 36-44 phosphodiesterase 5A Homo sapiens 19-23 32663396-2 2020 Here, we report the crystal structure of PDE5 complexed with the sole second generation drug avanafil. avanafil 93-101 phosphodiesterase 5A Homo sapiens 41-45 32604853-1 2020 Avanafil (AVA) is a second-generation phosphodiesterase-5 (PDE5) inhibitor. avanafil 0-8 phosphodiesterase 5A Homo sapiens 38-57 32604853-1 2020 Avanafil (AVA) is a second-generation phosphodiesterase-5 (PDE5) inhibitor. avanafil 0-8 phosphodiesterase 5A Homo sapiens 59-63 32604853-1 2020 Avanafil (AVA) is a second-generation phosphodiesterase-5 (PDE5) inhibitor. avanafil 10-13 phosphodiesterase 5A Homo sapiens 38-57 32604853-1 2020 Avanafil (AVA) is a second-generation phosphodiesterase-5 (PDE5) inhibitor. avanafil 10-13 phosphodiesterase 5A Homo sapiens 59-63 30029473-1 2018 Avanafil (AVA), one of the most effective drugs prescribed for erectile dysfunction, is a pyrimidine-derivative PDE5 inhibitor. avanafil 0-8 phosphodiesterase 5A Homo sapiens 112-116 30029473-1 2018 Avanafil (AVA), one of the most effective drugs prescribed for erectile dysfunction, is a pyrimidine-derivative PDE5 inhibitor. avanafil 10-13 phosphodiesterase 5A Homo sapiens 112-116 29275958-13 2018 Avanafil, a 2nd-generation PDE5i with a good balance between efficacy and tolerability profile, is more frequently prescribed by doctors than self-prescribed compared with other PDE5is. avanafil 0-8 phosphodiesterase 5A Homo sapiens 27-31 28213937-4 2018 There are currently four PDE5 inhibitors available for the treatment of erectile dysfunction: sildenafil, vardenafil, tadalafil and avanafil. avanafil 132-140 phosphodiesterase 5A Homo sapiens 25-29 27232892-8 2016 Expert commentary: Avanafil is a potent, highly selective PDE5I whose efficacy is comparable to that of currently available PDE5Is in both naive and previous PDE5I users. avanafil 19-27 phosphodiesterase 5A Homo sapiens 58-62 27232892-10 2016 Avanafil has high selectivity for the PDE5 isoenzyme, thus resulting in a lower incidence of drug-related side effects compared to other PDE5Is. avanafil 0-8 phosphodiesterase 5A Homo sapiens 38-42 27416913-3 2016 Avanafil, the only United States and European Union-approved second-generation PDE5 inhibitor, is a safe and efficacious alternative to its predecessors. avanafil 0-8 phosphodiesterase 5A Homo sapiens 79-83 27871960-2 2016 Oral PDE-5 inhibitors such as sildenafil, vardenafil, tadalafil, and avanafil have provided noninvasive, effective, well-tolerated treatment for erectile dysfunction (ED) patients and, at the same time, stimulated both academic and clinical interests. avanafil 69-77 phosphodiesterase 5A Homo sapiens 5-10 25582903-2 2014 OBJECTIVES: Avanafil is a highly selective phosfosdiesterase 5 inhibitor (PDE5 inhibitor), with rapid onset of action, approved by the Food and Drug Administration (FDA) and the European Medicines Agency for the treatment of erectile dysfunction (ED). avanafil 12-20 phosphodiesterase 5A Homo sapiens 74-78 25801159-2 2015 Sildenafil, vardenafil, tadalafil and avanafil are FDA approved drugs in market as PDE5 inhibitors for treating erectile dysfunction. avanafil 38-46 phosphodiesterase 5A Homo sapiens 83-87 25582903-13 2014 CONCLUSIONS: Avanafil is a selective PDE5 inhibitors, that is rapidly absorbed and that has a short time to peak response. avanafil 13-21 phosphodiesterase 5A Homo sapiens 37-41 24589460-1 2014 Avanafil, a potent new selective phosphodiesterase type 5 (PDE5) inhibitor, has been developed for the treatment of erectile dysfunction (ED). avanafil 0-8 phosphodiesterase 5A Homo sapiens 33-57 24818838-0 2014 Avanafil (Stendra)--another PDE5 inhibitor for erectile dysfunction. avanafil 0-8 phosphodiesterase 5A Homo sapiens 28-32 24818838-0 2014 Avanafil (Stendra)--another PDE5 inhibitor for erectile dysfunction. avanafil 10-17 phosphodiesterase 5A Homo sapiens 28-32 24589460-1 2014 Avanafil, a potent new selective phosphodiesterase type 5 (PDE5) inhibitor, has been developed for the treatment of erectile dysfunction (ED). avanafil 0-8 phosphodiesterase 5A Homo sapiens 59-63 23656343-3 2013 PDE inhibitors, in particular the PDE5 (cyclic GMP PDE) inhibitors avanafil, lodenafil, sildenafil, tadalafil, udenafil and vardenafil, are regarded as efficacious, having a fast onset of drug action and an improved effect-to-adverse event ratio, combining a high response rate with the advantage of an on-demand intake. avanafil 67-75 phosphodiesterase 5A Homo sapiens 34-38 26558086-3 2013 New PDE5 inhibitors, including avanafil and udenafil, are now in clinical use in a few countries, and other compounds are under development. avanafil 31-39 phosphodiesterase 5A Homo sapiens 4-8 24259695-6 2013 DATA SYNTHESIS: Avanafil is a highly selective PDE5 inhibitor that is a competitive antagonist of cyclic guanosine monophosphate. avanafil 16-24 phosphodiesterase 5A Homo sapiens 47-51 24259695-7 2013 Specifically, avanafil has a high ratio of inhibiting PDE5 as compared with other PDE subtypes allowing for the drug to be used for ED while minimizing adverse effects. avanafil 14-22 phosphodiesterase 5A Homo sapiens 54-58 24259695-13 2013 A network meta-analysis comparing the PDE5 inhibitors revealed avanafil was less effective on Global Assessment Questionnaire question 1 while safety data indicated no major differences among the different PDE5 inhibitors. avanafil 63-71 phosphodiesterase 5A Homo sapiens 38-42 24259695-15 2013 CONCLUSIONS: Avanafil is a potent PDE5 inhibitor and is an effective treatment option for ED. avanafil 13-21 phosphodiesterase 5A Homo sapiens 34-38 22248153-2 2012 AIM: To prospectively evaluate the safety and efficacy of avanafil, a novel PDE5 inhibitor, in men with mild to severe ED. avanafil 58-66 phosphodiesterase 5A Homo sapiens 76-80 22759639-0 2012 Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability. avanafil 15-23 phosphodiesterase 5A Homo sapiens 27-31 22759639-2 2012 Data from in vitro studies showed that avanafil, a PDE5 inhibitor for the treatment of ED, exhibited strong selectivity toward PDE5 and against all other PDE isozymes. avanafil 39-47 phosphodiesterase 5A Homo sapiens 51-55 22759639-2 2012 Data from in vitro studies showed that avanafil, a PDE5 inhibitor for the treatment of ED, exhibited strong selectivity toward PDE5 and against all other PDE isozymes. avanafil 39-47 phosphodiesterase 5A Homo sapiens 127-131 22759639-6 2012 RESULTS: Avanafil is highly selective toward PDE5 and against all other PDE isozymes tested. avanafil 9-17 phosphodiesterase 5A Homo sapiens 45-49 22759639-8 2012 CONCLUSIONS: Data suggest that avanafil may confer a safety benefit, in terms of a lower incidence of specific adverse events, by virtue of its high specificity to PDE5 and its overall selectivity against other PDE isozymes. avanafil 31-39 phosphodiesterase 5A Homo sapiens 164-168 22448738-4 2012 Avanafil is a potent selective phosphodiesterase type 5 (PDE5) inhibitor newly developed for treating erectile dysfunction (ED). avanafil 0-8 phosphodiesterase 5A Homo sapiens 31-55 22448738-4 2012 Avanafil is a potent selective phosphodiesterase type 5 (PDE5) inhibitor newly developed for treating erectile dysfunction (ED). avanafil 0-8 phosphodiesterase 5A Homo sapiens 57-61 22448738-5 2012 Preclinical and clinical phase I studies showed that avanafil had enhanced selectivity, faster onset of action and a favourable side-effect profile relative to currently available PDE5 inhibitors. avanafil 53-61 phosphodiesterase 5A Homo sapiens 180-184 22448738-7 2012 OBJECTIVE: To evaluate the efficacy and safety of avanafil, a new potent selective phosphodiesterase type 5 (PDE5) inhibitor, in patients with erectile dysfunction (ED). avanafil 52-60 phosphodiesterase 5A Homo sapiens 85-109 22448738-7 2012 OBJECTIVE: To evaluate the efficacy and safety of avanafil, a new potent selective phosphodiesterase type 5 (PDE5) inhibitor, in patients with erectile dysfunction (ED). avanafil 52-60 phosphodiesterase 5A Homo sapiens 111-115 18197727-5 2008 In addition, several new PDE5 inhibitors are candidates to enter the market in forthcoming years (avanafil, udenafil, SLx-2101, mirodenafil [SK3530]). avanafil 98-106 phosphodiesterase 5A Homo sapiens 25-29 22384456-5 2012 Avanafil is a novel PDE5 inhibitor with favorable pharmacokinetic and pharmacodynamic profiles with good tolerability and limited adverse events. avanafil 0-8 phosphodiesterase 5A Homo sapiens 20-24 22087063-5 2011 A special emphasis is on avanafil, a new PDE5 inhibitor that has been studied extensively in Phase I and II clinical trials and has undergone several Phase III trials. avanafil 25-33 phosphodiesterase 5A Homo sapiens 41-45 20939743-5 2010 AREAS COVERED IN THIS REVIEW: Preclinical and clinical studies of avanafil, a new oral PDE5 inhibitor being investigated for the treatment of ED. avanafil 66-74 phosphodiesterase 5A Homo sapiens 87-91 20939743-8 2010 TAKE HOME MESSAGE: We propose that avanafil, which displays enhanced selectivity, faster onset of action, and a favorable side-effect profile relative to currently available PDE5 inhibitors, may offer an alternative first line treatment option for men with ED. avanafil 35-43 phosphodiesterase 5A Homo sapiens 174-178